Biogen (BIIB) Other Non-Current Liabilities (2009 - 2026)
Biogen (BIIB) posted quarterly Other Non-Current Liabilities of $820.9 million for Q2 2026, up 2.66% year-over-year from $799.6 million in Q2 2025, and up 4.29% quarter-over-quarter from $787.1 million in Q1 2026.
Biogen (BIIB) Other Non-Current Liabilities (2009 - 2026) Analysis & Trends
Biogen's Other Non-Current Liabilities history runs 18 years deep, the most recent figure standing at $820.9 million for Q2 2026.
- In Q2 2026, Other Non-Current Liabilities rose 2.66% year-over-year to $820.9 million; the TTM figure through Jun 2026 stood at $820.9 million (up 2.66% YoY), while the FY2025 annual figure was $748.5 million, up 2.21% from the prior year.
- Other Non-Current Liabilities for Q2 2026 stood at $820.9 million, up from $787.1 million in the prior quarter.
- The five-year high for Other Non-Current Liabilities was $1.3 billion in Q1 2022, with the low at $556.7 million in Q2 2024.
- The 5-year median for Other Non-Current Liabilities is $779.1 million (2023), against an average of $851.1 million.
- The sharpest annual moves came in 2023 and 2025: Other Non-Current Liabilities tumbled 37.58% in 2023, then surged 43.63% in 2025.
- Biogen's Other Non-Current Liabilities stood at $944.2 million in 2022, then declined by 17.27% to $781.1 million in 2023, then retreated by 6.25% to $732.3 million in 2024, then rose by 2.21% to $748.5 million in 2025, then advanced by 9.67% to $820.9 million in 2026.
- Business Quant data shows BIIB's Other Non-Current Liabilities at $820.9 million in Q2 2026, $787.1 million in Q1 2026, and $748.5 million in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Johnson & Johnson | 652.20 Bn | 631.44 Bn | 17.26 Bn |
| 2 | AbbVie | 469.51 Bn | 462.94 Bn | 12.70 Bn |
| 3 | Merck | 376.81 Bn | 369.67 Bn | 12.21 Bn |
| 4 | Novartis Ag | 303.04 Bn | 295.35 Bn | 11.24 Bn |
| 5 | Astrazeneca | 257.61 Bn | 252.71 Bn | 12.86 Bn |
| 6 | Amgen | 237.37 Bn | 223.38 Bn | 7.24 Bn |
| 7 | Gilead Sciences | 181.73 Bn | 178.55 Bn | 6.22 Bn |
| 8 | Pfizer | 159.66 Bn | 147.96 Bn | 10.94 Bn |
| 9 | Gsk | 106.24 Bn | 102.07 Bn | 8.24 Bn |
| 10 | Biogen | 32.04 Bn | 30.76 Bn | 1.96 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 820.90 Mn |
| Mar 31, 2026 | 787.10 Mn |
| Dec 31, 2025 | 748.50 Mn |
| Sep 30, 2025 | 761.80 Mn |
| Jun 30, 2025 | 799.60 Mn |
| Mar 31, 2025 | 751.70 Mn |
| Dec 31, 2024 | 732.30 Mn |
| Sep 30, 2024 | 744.10 Mn |
| Jun 30, 2024 | 556.70 Mn |
| Mar 31, 2024 | 777.10 Mn |
| Dec 31, 2023 | 781.10 Mn |
| Sep 30, 2023 | 747.90 Mn |
| Jun 30, 2023 | 776.90 Mn |
| Mar 31, 2023 | 935.50 Mn |
| Dec 31, 2022 | 944.20 Mn |
| Sep 30, 2022 | 1.20 Bn |
| Jun 30, 2022 | 1.17 Bn |
| Mar 31, 2022 | 1.29 Bn |
| Dec 31, 2021 | 1.32 Bn |
| Sep 30, 2021 | 1.32 Bn |